Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives

Biomedical Chromatography

Volumn 24, Issue 1, 2010, Pages 104-123

  Mullangi, Ramesh ^a   Ahlawat, Preeti ^b   Srinivas, Nuggehally R ^c  

^a Jubilant Innovation   (India)

^b ClinTec India International Pvt Ltd   (India)

^c Suramus Biopharm   (India)

Author keywords

Anti cancer; HPLC; Irinotecan; LC MS; LC MS MS; Pharmacodynamics; Pharmacokinetics; SN 38

Indexed keywords

BIOMOLECULES; DISEASES; DRUG INTERACTIONS; ONCOLOGY; PHARMACOKINETICS;

ACTIVE METABOLITES; ANTI-CANCER; BIOANALYTICAL METHODS; CLINICAL PHARMACOLOGY; HPLC; IRINOTECAN; LC-MS; LC-MS-MS; LC.MS/MS; SN-38;

METABOLITES;

2 PROPANOL; 6BETA HYDROXYHYDROCORTISONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETIC ACID ETHYL ESTER; BILIRUBIN; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ACID; CYTOCHROME P450 3A4; DICHLOROMETHANE; GLUCURONOSYLTRANSFERASE 1A1; HEXANE; HYDROCORTISONE; IRINOTECAN; LACTONE; LOPINAVIR PLUS RITONAVIR; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; BILE DUCT; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL PHARMACOLOGY; CREATININE CLEARANCE; DIARRHEA; DNA POLYMORPHISM; DRUG CONTAMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPOSI SARCOMA; KIDNEY FUNCTION; NEUTROPENIA; NONHUMAN; PH; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 75149150270     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1345     Document Type: Review

References (77)

1. Bansal T, Awasthi A, Jaggi M, Khar RK and Talegaonkar S. Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantifi cation of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. Talanta 2008a; 76: 1015-1021.
2. Bansal T, Awasthi A, Jaggi M, Khar RK and Talegaonkar S. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sciences 2008b; 83: 250-259.
3. Bansal T, Awasthi A, Jaggi M, Khar RK and Talegaonkar S. Eff ect of Pglycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. European Journal of Pharmaceutical Sciences 2009; 36: 580-590.
4. Bardin S, Guo W, Johnson JL, Khan S, Ahmad A, Duggan JX, Ayoub J and Ahmad I. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantifi cation of Camptosar and its metabolite SN-38 in mouse plasma and tissues. Journal of Chromatography A 2005; 1073: 249-255.
5. Barilero I, Gandia D, Armand JP, Mathieu-Boue A, Re M, Gouyette A and Chabot GG. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. Journal of Chromatography B 1992; 575: 275-280.
6. Boyd G, Smyth JF, Jordell JI and Cummings J. High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells. Analytical Biochemistry 2001; 297: 15-24.
7. Burke TG and Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Analytical Biochemistry 1993; 212: 285-287.
8. Burke TG and Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Journal of Medicinal Chemistry 1994; 37: 40-46
9. Burke TG, Munshi CB, Mi Z and Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. Journal of Pharmaceutical Sciences 1995; 84: 518-519.
10. Candussio L, Decorti G, Crivellato E, Granzotto M, Rosati A, Giraldi T and Bartoli F. Toxicology and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sceinces 2002; 71: 3109-3119.
11. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M and Clavel M. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Annals of Oncology 1995; 6: 133-140.
12. Choi JS and Li X. The eff ect of verapamil on the pharmacokinetics of paclitaxel in rats. European Journal of Pharmaceutical Sciences 2005; 24: 95-100.
13. Chollet DF, Goumaz L, Renard A, Montay G, Vernillet L, Arnera V and Mazzo DJ. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. Journal of Chromatography B 1998; 718: 163-175.
14. Combes O, Barre J, Duche JC, Vernillet L, Archimbaud Y, Marietta MP, Tillement JP and Urien S. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Investigational New Drugs 2000; 18: 1-5.
15. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F and Toff oli G. Lopinavir-ritonavir dramatically aff ects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clinical Pharmacology and Therapeutics 2008; 83: 601-606.
16. de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G and Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fl uorescence detection. Journal of Chromatography B 1997; 698: 277-285.
17. D'Esposito F, Tattam BN, Ramzan I and Murray M. A liquid chromatography/ electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. Journal of Chromatography B 2008; 875: 522-530.
18. de Jong FA, Mathiissen RH, de Bruijn P, Loos WJ, Verweij J and Sparreboom A. Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fl uorescence detection. Journal of Chromatography B 2003; 795: 383-388.
19. de Jong FA, Kitzen JJ, de Bruijn P, Verweij J and Loos WJ. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biology and Therapy 2006; 5: 1105-1110.
20. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A and Verweij J. Renal function as a predictor of irinotecan-induced neutropenia. Clinical Pharmacology and Therapeutics 2008; 84: 254-262.
21. de Jonge MJA, Sparreboom A and Verweij J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treatment Reviews 1998; 24: 205-220.
22. Dodds HM, Haaz MC, Riou JF, Robert J and Rivory LP. Identifi cation of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. Journal of Pharmacology and Experimental Therapeutics 1998; 286: 578-583.
23. Escoriaza J, Aldaz A, Castellanos C, Calvo E and Giraldez J. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. Journal of Chromatography B 2000; 740: 159-168.
24. Fassberg J and Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. Journal of Pharmaceutical Sciences 1992; 81: 676-684.
25. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S and Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. Journal of Clinical Oncology 1992; 10: 16-20.
26. Gravel E, Bourget P, Mercier L and Paci A. Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives. Journal of Pharmaceutical and Biomedical Analysis 2005; 39: 581-586.
27. Guo W, Yang XX, Chen X, Duan W and Zhou SF. Determination by liquid chromatography with fl uorescence detection of total 7-ethyl-10-hydroxy- camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38). Journal of Chromatography B 2003; 791: 85-92.
28. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE and Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Research 1994; 54: 3723-3725.
29. Haaz MC, Rivory C, Riche C, Vernillet L and Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Research 1998; 58: 468-472.
30. Hu ZP, Yang XX, Chen X, Chan E, Duan W and Zhou SF. Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies. Journal of Chromatography B 2007; 850: 575-580.
31. Itoh T, Itagaki S, Sumi Y, Hirano T, Takemoto I and Iseki K. Update of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemotherapy and Pharmacology 2005; 55: 420-424.
32. Iyer L, King CD, Whitington PF, Green MD, Tephly TR, Coff man BL and Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform1A1 in the glucuronidation of its active metabolite (SN-28) in human liver microsomes. Journal of Clinical Investigations 1998; 101: 847-854.
33. Iyer L, Ramírez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ and Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glyco- protein-defi cient mice. Cancer Chemotherapy and Pharmacology 2002; 49: 336-341.
34. Kaneda N, Hosokawa Y and Yokokura T. Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography. Biological and Pharmaceutical Bulletin 1997; 20: 815-819.
35. Khan S, Ahmad A and Ahmad I. A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl- 10-hydroxycamptothecin (SN-38) in human plasma containing liposome- based SN-38 (LE-SN38). Biomedical Chromatography 2003; 17: 493-499.
36. Khan S, Ahmad A, Guo W, Wang YF, Abu-Qare A and Ahmad I. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 135-142.
37. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ and Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clinical Pharmacology and Therapeutics 2002; 72: 638-647.
38. Kurita A and Kaneda N. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. Journal of Chromatography B 1999; 724: 335-344.
39. Liu X, Wang L, Vardeman D, Cao Z and Giovanella B. Development and validation of a reverse-phase HPLC with fl uorescence detector method for simultaneous determination of CZ48 and its active metabolite camptothecin in mouse plasma. Journal of Chromatography B 2008; 867: 84-89.
40. Lokiec F, du Sorbier BM and Sanderink GJ. Irinotecan (CPT-11) metabolites in human bile and urine. Clinical Cancer Research 1996; 2: 1943-1949.
41. Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK and Sparreboom A. Role of erythrocytes and serum proteins in the kinetic profi le of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs 1999; 10: 705-710.
42. Ma MK and McLeod HL. Lessons learned from the irinotecan metabolic pathway. Current Medicinal Chemistry 2003; 10: 41-49.
43. Manjunath Swamy J, Kamath N, Anil Kumar, Shekar R, Srinivas NR and Kristijansson F. Sensitivity enhancement and matrix eff ect evaluation during summation of multiple transition pairs-case studies of clopidogrel and ramiprilat. Biomedical Chromatography 2009; DOI: 10.1002/bmc.1322.
44. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y and Oguro M. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. Journal of Clinical Oncology 1990; 8: 1907-1912.
45. Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, Kato I and Yokokura T. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemotherapy and Pharmacology 2008; 61: 595-605.
46. Owens TS, Dodds H, Fricke K, Hanna SK and Crews KR. High-performance liquid chromatographic assay with fl uorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. Journal of Chromatography B 2003; 788: 65-74.
47. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anticancer drug treatment. Current Medicinal Chemistry 2006; 13: 1859-1876.
48. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Research 1994; 54: 1431-1439.
49. Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S and Bressolle F. Sensitive HPLC-fl uorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clinical Chemistry 2003; 49: 1900-1908.
50. Ragot S, Marquet P, Lachatre F, Rousseau A, Lacassie E, Gaulier JM, Dupuy JL and Lachatre G. Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B, 1999; 736: 175-184.
51. Redinbo MR, Stewart L, Kuhn P, Champoux JJ and Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-1513.
52. Rivory LP and Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. Journal of Chromatography B 1994; 661: 133-141.
53. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A and Robert J. Kinetics of the in vivo interconversion. Cancer Research 1994; 54: 6330-6333.
54. Rivory LP, Findlay M, Clarke S and Bishop J. Reversed-phase highperformance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. Journal of Chromatography B 1998; 714: 355-359.
55. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commerçon A, Pond SM and Robert J. Identifi cation and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Research 1996; 56: 3689-3694.
56. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J and Gamelin E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British Journal of Cancer 2008; 99: 1239-1245.
57. Sai K, Kaniwa N, Ozawa S and Sawada J. A new metabolite of irinotecan whose formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metabolism and. Disposition 2001; 29: 1505-1513.
58. Sai K, Kaniwa N, Ozawa S and Sawada J. An analytical method for irinotecan (CPT- 11) and its metabolites using a high-performance liquid chromatography: parallel detection with fl uorescence and mass spectrometry. Biomedical Chromatography 2002; 16: 209-218.
59. Sano K, Yoshikawa M, Hayasaka S, Satake K, Ikegami Y, Yoshida H, Ishikawa T, Sawada S and Tanabe S. Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. Journal of Chromatography B 2003; 795: 25-34.
60. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A and Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clinical Cancer Research 2000; 6: 2012-2020.
61. Schoemaker NE, Rosing H, Jansen S, Schellens JH and Beijnen JH. Highperformance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. Therapeutic Drug Monitoring 2003; 25: 120-124.
62. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. Journal of Clinical Oncology 1993; 11: 909-913.
63. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV and Lord RS 3rd. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug Metabolism and Disposition 2000; 28: 423-433.
64. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH. The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute 1993; 85: 271-291.
65. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G and Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clinical Cancer Research 1998a; 4: 2747-2754.
66. Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J and Nooter K. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. Journal of Chromatography B 1998b; 712: 225-235.
67. Srinivas NR. Dodging matrix eff ects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomedical Chromatography 2009a; 23: 451-454.
68. Srinivas NR. Sensitivity enhancement in tandem liquid chromatographic mass spectrometric assays by summation of two transition ion pairs-perspectives. Journal of Separation Sciences 2009b; 32: 483-486.
69. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M and Warhurst G. Kinetic profi ling of P-glycoprotein-mediated drug effl ux in rat and human intestinal epithelia. Journal of Pharmacology and Experimental Therapeutics 2001; 296: 584-591.
70. Stewart L, Redinbo MR, Qiu X, Hol WG and Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998; 279: 1534-1541.
71. Sugiyama Y, Kato Y and Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecifi c organic anion transporter and P-glycoprotein. Cancer Chemotherapy and. Pharmacology 1998; 42(suppl.): S44-49.
72. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Tamura K and Yamakido M. High- performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. Journal of Chromatography B 1995; 670: 309-316.
73. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM and Mondick J. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemotherapy and Pharmacology 2008; 62: 1027-1037.
74. Xuan T, Zhang JA and Ahmad I. HPLC method for determination of SN-38 content and SN-38 entrapment effi ciency in a novel liposome-based formulation, LE-SN38. Journal of Pharmaceutical Biomedical Analysis 2006; 41: 582-588.
75. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N and Saijo N. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. Journal of Clinical Oncology 2005; 23: 1061-1069.
76. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M and Lin JH. In vitro substrate identifi cation studies for p-glycoproteinmediated transport: species diff erence and predictability of in vivo results. Journal of Pharmacology and Experimental Therapeutics 2001; 296: 723-735.
77. Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E and Zhou S. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. Journal of Chromatography B 2005; 821: 221-228.